AstraZeneca Pharma India Limited Overview
AstraZeneca Pharma India Limited is the publicly listed Indian commercial arm of AstraZeneca PLC, operating as a specialty, innovation-only pharmaceutical marketer focused on Oncology, Biopharmaceuticals (Cardiovascular, Renal & Metabolism; Respiratory & Immunology; Vaccines & Immune Therapies) and, since FY2025, Rare Disease (Alexion portfolio). Unlike India's generic-led majors, AZPIL sells patented and branded medicines sourced predominantly from its parent's global supply network, and it has now completed its exit from in-country manufacturing (Bengaluru site). Revenue has compounded at roughly 30% a year since FY2022, reaching INR 22,756 M in FY2026, driven overwhelmingly by oncology brands, which grew 44% to INR 16,101 M. The company secured 11 regulatory approvals for new medicines and indications in FY2026. The investment case combines best-in-class top-line growth and a debt-free balance sheet against thin, compressing margins, heavy related-party sourcing, price-control exposure, recent senior-management turnover, and a valuation near 100x trailing earnings.
Company's own description
Exchange-filed descriptions characterise the company as engaged in the manufacture, distribution and marketing of pharmaceutical products, and also as a provider of clinical-trial services to an overseas group company (FY2025 Annual Report, as quoted by aggregators). The company's October 2026 press release describes the AstraZeneca organisation in India as science-led, focused on discovery, development and commercialisation of prescription medicines across Oncology, Biopharmaceuticals and Rare Disease, with operations in India spanning commercial operations, site management and clinical monitoring, technology, R&D and global business services.
Independent characterisation
AZPIL is best understood as a "pipeline-import, commercialise-locally" model:
-
Product sourcing. Finished medicines are imported from AstraZeneca group entities (principally AstraZeneca AB, Sweden and AstraZeneca UK). Related-party transactions with these entities were reported by one analysis at about 72.9% of FY2025 revenue (CompoundingAI, Q1 FY2027 results note) — this is the scale of related-party flows (mostly purchases), not revenue from those parties. AZPIL is Marketing Authorisation Holder (MAH) and import-licence holder in India for the molecules it markets.
-
Regulatory gateway. AZPIL files for import and marketing permission with India's Central Drugs Standard Control Organisation (CDSCO) for each new molecule or indication from the global pipeline. FY2026 saw 11 approvals; the group cites 25+ new medicines/indications launched in India over three years (press release, 16 Oct 2026).
-
Commercialisation. Specialty field force calling on oncologists, cardiologists, nephrologists, pulmonologists and hospital formularies, increasingly supplemented by brand-partnership (co-marketing) agreements with large domestic companies (Sun Pharma, Mankind Pharma) for mass-market molecules where AZPIL lacks reach.
-
Services revenue. Clinical-trial services provided to an overseas group company (the group runs about 80 global clinical trials in India per October 2026 release).
-
Manufacturing. Historically a tablet manufacturing/packaging site at Yelahanka, Bengaluru. Exit announced Nov 2023; manufacturing licence surrendered Sept 2025; exit completed during FY2026.
Revenue model mix
| Revenue type | Description | FY2026 disclosure |
|---|---|---|
| Product sales (patented/branded Rx) | Oncology, Biopharmaceuticals, Rare Disease brands | ~INR 21,559 M across three therapy areas (computed from disclosed TA revenue) |
| Services | Clinical-trial services to group company | Not separately disclosed in materials reviewed |
| Licensing / distribution fees | Upfront/consideration from co-marketing partners (e.g., INR 260 M payable under the Nov 2025 Sun Pharma SZC agreement) | — |
| Subscription | — | — |
Customers and end-markets
Direct customers: pharmaceutical distributors/stockists (C&F agents), hospitals and institutional buyers (including government tenders for some brands), and co-marketing partners (Sun Pharma, Mankind Pharma) to whom AZPIL supplies product.
Prescribers: medical/surgical oncologists, haemato-oncologists, cardiologists, nephrologists, endocrinologists/diabetologists, pulmonologists, rare-disease specialists.
End-market: the Indian Pharmaceutical Market (IPM), specifically the premium innovator/specialty segment, which is a small share of the generics-dominated IPM by volume but growing faster in value. Patient affordability is a constraint; most oncology therapy is out-of-pocket or insurance-funded, with patient-access programmes playing a material role.
Value-chain position
AZPIL sits at the last mile of AstraZeneca's global value chain: discovery, development and manufacturing occur largely outside the listed entity; AZPIL captures a distribution/commercialisation margin governed by transfer pricing with the parent.
Strategy
Stated strategy (themes from company communications)
- Pioneer in science, lead in specialist disease areas, transform patient outcomes — the recurring articulation of ambition in filings since 2023.
Accelerate the global pipeline into India: 11 approvals in FY2026; 25+ new medicines/indications in three years.
Focus on three therapy areas: Oncology, Biopharmaceuticals (CVRM, R&I, V&I) and Rare Disease.
New access pathways: working with governments and industry, leveraging AI and solutions across prevention, awareness, diagnosis and treatment (Oct 2026 release); earlier screening and guideline-directed therapy in CVRM.
Asset-light operating model: exit from manufacturing to rely on the global supply network.
Partnership-led reach: brand partnerships with Sun Pharma and Mankind for mass-market molecules.
Geographic penetration: expansion into Tier II/III markets, field-force expansion and digital physician engagement (aggregator description of growth strategy).
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Status |
|---|---|---|---|
| Manufacturing exit, Bengaluru | Nov 2023 – FY2026 | Exit site; seek buyer; surrender licence | Exit completed FY2026; buyer not confirmed |
| Restructuring | Late 2024 | >125 roles reportedly eliminated | Completed |
| Leadership transition | Jul 2025 | Oncology head promoted to MD | In place |
| Lokelma launch + Sun Pharma partnership | Nov 2025 | Hyperkalaemia franchise with second-brand partner | Live |
| Oncology label expansions | Oct 2025 – 2026 | Enhertu (HER2+), Calquence (CLL/SLL; MCL) | Approved |
| Fasenra label expansions | May & Jul 2026 | EGPA; HES 12+ | Approved |
| Rare Disease build-out | FY2025 – FY2027 | Revenue scaled from ~INR 31 M (implied FY2025) to INR 144 M in a single quarter | Scaling |
| Corporate Affairs strengthening | Jul 2026 | Hire of ex-FICCI policy leader | In place |
| Mumbai commercial office | Oct 2026 | 25,600 sq ft office; stakeholder engagement and talent | Opened |
| Investor engagement | Aug 2026 | Virtual analyst/investor interaction on 19 Aug 2026 | Held |
Medium-term targets / guidance
AZPIL does not publish numerical revenue or margin guidance. Management commentary is qualitative (sustained innovation-led growth). Parent AstraZeneca PLC's global ambitions (e.g., multi-year revenue targets) are not India-specific and are not reproduced here.
Products & Services
Oncology
| Brand (molecule) | Description / mechanism | Key indications | Target prescriber | Latest India milestone |
|---|---|---|---|---|
| Tagrisso (osimertinib) | Third-generation EGFR tyrosine-kinase inhibitor, oral | EGFR-mutated non-small cell lung cancer (NSCLC), adjuvant and metastatic | Medical oncologists | Flagship growth brand [global portfolio]; latest India label expansions not itemised in materials reviewed |
| Imfinzi (durvalumab) | Anti-PD-L1 immunotherapy, IV | NSCLC, small-cell lung cancer, biliary tract, hepatocellular carcinoma, others | Oncologists | Additional CDSCO approvals referenced during FY2026 [filed, per aggregator summary] |
| Imjudo (tremelimumab) | Anti-CTLA-4, used with Imfinzi | Hepatocellular carcinoma, NSCLC | Oncologists | — |
| Lynparza (olaparib) | PARP inhibitor, oral (co-commercialised globally with MSD) | BRCA-mutated ovarian, breast, prostate, pancreatic cancers | Gynae-oncologists, oncologists | [global portfolio] |
| Calquence (acalabrutinib) 100 mg tablets | Second-generation BTK inhibitor | Untreated CLL/SLL in combination with venetoclax ± obinutuzumab (CDSCO, Apr 2026); untreated mantle cell lymphoma in transplant-ineligible patients (CDSCO, 2026) | Haemato-oncologists | [filed] two 2026 approvals |
| Enhertu (trastuzumab deruxtecan) 100 mg/5 mL | HER2-directed antibody-drug conjugate (with Daiichi Sankyo) | HER2-positive and HER2-low breast cancer; additional HER2-positive indication approved 3 Oct 2025 | Oncologists | [filed] Oct 2025 |
| Zoladex (goserelin) | LHRH agonist implant | Prostate and breast cancer | Oncologists, urologists | Mature brand [global portfolio] |
| Faslodex (fulvestrant) | Selective oestrogen-receptor degrader, injection | HR+ advanced breast cancer | Oncologists | Mature; generic competition [global portfolio] |
| Truqap (capivasertib) | AKT inhibitor | HR+/HER2- advanced breast cancer with pathway alterations | Oncologists | — |
| Datroway (datopotamab deruxtecan) | TROP2-directed ADC | Breast cancer, NSCLC | Oncologists | — |
Biopharmaceuticals — Cardiovascular, Renal & Metabolism (CVRM)
| Brand (molecule) | Description | Indications | Notes |
|---|---|---|---|
| Forxiga (dapagliflozin) | SGLT2 inhibitor, oral | Type 2 diabetes, heart failure, chronic kidney disease | Historic largest Biopharma brand; dapagliflozin faces Indian generic competition; Sun Pharma owns Oxra/Oxramet/Oxraduo brands since 2021 |
| Xigduo (dapagliflozin + metformin) | Fixed-dose combination | Type 2 diabetes | [global portfolio] |
| Brilinta (ticagrelor) | P2Y12 antiplatelet | Acute coronary syndrome | Reached 9.7% segment share by FY2015 per annual report |
| Betaloc / Betaloc ZOK (metoprolol) | Beta-blocker | Hypertension, angina, heart failure | Price-controlled; subject of NPPA overcharge demand (Betaloc-50), stayed by Delhi High Court (Aug 2026) |
| Lokelma (sodium zirconium cyclosilicate) 5 g powder for oral suspension | Potassium binder | Hyperkalaemia (CKD, heart failure on RAAS inhibitors) | Launched Nov 2025; co-marketed by Sun Pharma as Gimliand under Nov 2025 agreement |
| Crestor (rosuvastatin) | Statin | Dyslipidaemia | Mature/genericised [global portfolio] |
Biopharmaceuticals — Respiratory & Immunology (R&I) and V&I
| Brand (molecule) | Description | Indications | Notes |
|---|---|---|---|
| Symbicort Turbuhaler (budesonide + formoterol) | ICS/LABA dry-powder inhaler | Asthma, COPD | Exclusive distribution by Mankind Pharma since Mar 2024; NPPA show-cause (Sep 2025) alleging INR 605 M overcharge |
| Fasenra (benralizumab) 30 mg/mL pre-filled syringe | Anti-IL-5 receptor biologic | Severe eosinophilic asthma; relapsing/refractory EGPA (CDSCO, 26 May 2026); hypereosinophilic syndrome in patients 12+ (CDSCO, 15–16 Jul 2026) | [filed] two 2026 label expansions |
| Breztri (budesonide/glycopyrronium/formoterol) | Triple-therapy inhaler | COPD | — |
| Pulmicort (budesonide) | Inhaled corticosteroid | Asthma | Mature [global portfolio] |
| Vaccines & Immune Therapies | V&I listed as part of Biopharmaceuticals in Q1 FY2027 disclosure | Specific V&I brands in India not itemised | — |
Rare Disease (Alexion, AstraZeneca Rare Disease)
| Brand (molecule) | Description | Indications | Notes |
|---|---|---|---|
| Soliris (eculizumab) | C5 complement inhibitor | PNH, aHUS, gMG, NMOSD | India commercial status in listed entity not itemised |
| Ultomiris (ravulizumab) | Long-acting C5 inhibitor | PNH, aHUS, gMG | — |
| Koselugo (selumetinib) | MEK inhibitor | Neurofibromatosis type 1 plexiform neurofibromas | — |
Rare Disease revenue: INR 215 M in FY2026; INR 144 M in Q1 FY2027.
Services
| Service | Description | Counterparty |
|---|---|---|
| Clinical-trial services | Site management, monitoring, safety and regulatory support for global trials | Overseas AstraZeneca group company; group runs ~80 global trials in India |
Financial Narrative
Primary source map: FY2026 and FY2025 headline numbers from company results releases (30 May 2025; 26 May 2026). Line items (cost of revenue, operating income) from StockAnalysis (standardised from filings). EBITDA and total income from Anand Rathi data pages. Book value/EPS from Bajaj Broking/Screener. Where aggregator standardisation differs from the company's reported presentation, this is noted.
Income statement: notes and sources
Notes: Total income FY2022–FY2026 per StockAnalysis "revenue as reported" and Anand Rathi (INR 820.36 / 1,029.07 / 1,330.33 / 1,756.92 / 2,304.07 crore). FY2024 PBT of INR 2,195.4 M and PAT INR 1,615.1 M from company filing; FY2022–FY2023 PBT from Screener (rounded crore). Diluted EPS equals basic (no dilutive instruments identified). FY2025 PAT includes the Bengaluru site-closure provision (exceptional); FY2026 PAT is "after exceptional items". EBITDA aggregator definition likely includes other income; treat as indicative.
Margins (computed on revenue from operations, %)
Revenue CAGR FY2022–FY2026: (22,756 / 8,056)^(1/4) − 1 = 29.6%. Ten-year revenue CAGR ~15% (INR 564 crore → INR 2,276 crore, per Craytheon).
Quarterly trajectory
Q3 FY2026 PAT: Anand Rathi shows INR 325.9 M; a CMOTS/Arihant note shows INR 315.5 M (−42.3% YoY) on net sales of INR 6,155.7 M — discrepancy noted; the four FY2026 quarters using INR 325.9 M sum exactly to the FY2026 PAT of INR 1,875.2 M, so that figure is preferred.
Balance sheet
Equity computed as book value per share × 25.0 M shares; FY2024 cross-checks to filing (share capital INR 50.0 M + other equity INR 7,069.2 M = INR 7,119.2 M).
Cash flow and capital returns
Capex should be structurally minimal after the manufacturing exit (office fit-outs, IT). Dividends declared = DPS × 25 M shares; payout = declared ÷ PAT. No buybacks identified.
Ratios
Interest coverage computed from StockAnalysis (interest expense INR 9.5 / 6.3 / 12.0 / 14.6 / 44.9 M — almost entirely lease interest). Screener reports ROCE 33.4% and ROE 23.6% (trailing basis); Craytheon reports FY2026 ROE 21.5%, consistent with the computation above.
Commentary on trends, inflections and drivers
Growth inflection (FY2023 onward): After a flat FY2022 (−1.0%), revenue accelerated to 24–33% annual growth for four consecutive years, led by oncology launches and label expansions (Tagrisso, Imfinzi, Lynparza, Enhertu, Calquence) and by a stepped-up approval cadence (11 in FY2026).
Gross-margin compression is structural, not cyclical: Standardised gross margin fell ~21 points from FY2023 to FY2026 as the mix shifted to imported high-cost oncology biologics/ADCs (where transfer prices leave a thinner distribution margin), the in-house manufacturing contribution disappeared, and price-controlled Biopharma brands were genericised. Operating leverage on fixed costs (SG&A grew only from INR 2,303 M to INR 2,653 M over four years) partially offset this, keeping operating margin in a 10–15% band.
FY2025 dip was exceptional: PAT fell 28% in FY2025 primarily due to site-closure provisions (Q1 FY2025 net loss of INR 117.9 M); FY2026 PAT rebounded 62% to INR 1,875 M.
Renewed margin pressure in 2026: Q4 FY2026 PAT fell 23% despite 20% revenue growth (total expenses +27%), and Q1 FY2027 PAT fell 32% despite 30% revenue growth, with EBITDA margin compressing ~820 bps to ~7.1%. Third-party analysis attributes this to inventory drawdown, elevated employee costs tied to management churn, and foreign-exchange headwinds on imports (CompoundingAI). This divergence is the single most important near-term financial issue.
Shareholder returns: Dividend per share has risen every year (INR 10 → 36), with payout normalising around 40–50% of PAT outside the FY2025 exceptional year.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Units
| Business unit | What it contains | Representative brands |
|---|---|---|
Oncology | Targeted small molecules, immuno-oncology, antibody-drug conjugates (ADCs), hormonal therapies | Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Zoladex |
Biopharmaceuticals | CVRM (Cardiovascular, Renal & Metabolism), R&I (Respiratory & Immunology), V&I (Vaccines & Immune Therapies) | Forxiga, Brilinta, Betaloc, Lokelma, Symbicort, Fasenra, Breztri |
Rare Disease | Alexion-derived complement inhibitors and other rare-disease therapies | — |
Other operating revenue (computed residual) | Revenue from operations not attributed to the three TAs — likely services, other operating income and minor brands | — |
Revenue by Segment
| Segment (INR Mn) | FY2025 | FY2026 |
|---|---|---|
Oncology revenue (INR Mn) | 11,181 | 16,101 |
Biopharmaceuticals revenue (INR Mn) | 4,891 | 5,243 |
Rare Disease revenue (INR Mn) | 31 | 215 |
Other operating revenue, residual (INR Mn) | 1,060 | 1,197 |
Total revenue from operations (INR Mn) | 17,163 | 22,756 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment share of revenue (%)
| Segment share of revenue (%) | FY2025 | FY2026 |
|---|---|---|
Oncology share (%) | 65.1 | 70.8 |
Biopharmaceuticals share (%) | 28.5 | 23.0 |
Rare Disease share (%) | 0.2 | 0.9 |
Other share (%) | 6.2 | 5.3 |
Segment YoY growth (%) | FY2026 | — |
Oncology growth (%) | 44.0 | — |
Biopharmaceuticals growth (%) | 7.2 | — |
Rare Disease growth (%) | 600 | — |
Total growth (%) | 32.6 | — |
Revenue by Segment (Quarterly)
| Segment (INR Mn) | Q1FY2026 | Q1FY2027 |
|---|---|---|
Oncology revenue (INR Mn) | 3,690 | 4,649 |
Biopharmaceuticals revenue (INR Mn) | 1,190 | 1,619 |
Rare Disease revenue (INR Mn) | 4 | 144 |
Other operating revenue, residual (INR Mn) | 379 | 416 |
Total revenue from operations (INR Mn) | 5,263 | 6,828 |
Income Statement and Per-Share Data
| Metric (INR Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Mn) | 8,056 | 10,030 | 12,955 | 17,163 | 22,756 |
Total income incl. other income (INR Mn) | 8,204 | 10,291 | 13,303 | 17,569 | 23,041 |
Cost of revenue, standardised (INR Mn) | 3,169 | 3,660 | 6,008 | 9,688 | 13,846 |
Gross profit, standardised (INR Mn) | 4,887 | 6,370 | 6,947 | 7,475 | 8,910 |
Operating income, standardised (INR Mn) | 694 | 1,489 | 1,714 | 2,148 | 2,337 |
EBITDA, aggregator (INR Mn) | 1,009 | 1,510 | 2,357 | 1,978 | 2,853 |
Profit before tax (INR Mn) | 830 | 1,340 | 2,195 | 1,564 | 2,522 |
Net income / PAT (INR Mn) | 616 | 993 | 1,615 | 1,157 | 1,875 |
Basic & diluted EPS (INR) | 24.64 | 39.72 | 64.60 | 46.30 | 75.01 |
Dividend per share (INR) | 10 | 16 | 24 | 32 | 36 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 60.7 | 63.5 | 53.6 | 43.6 | 39.2 |
Operating margin (%) | 8.6 | 14.8 | 13.2 | 12.5 | 10.3 |
EBITDA margin (%) | 12.5 | 15.1 | 18.2 | 11.5 | 12.5 |
Pre-tax margin (%) | 10.3 | 13.4 | 16.9 | 9.1 | 11.1 |
Net margin (%) | 7.6 | 9.9 | 12.5 | 6.7 | 8.2 |
Revenue growth YoY (%) | -1.0 | 24.5 | 29.2 | 32.5 | 32.6 |
Net income growth YoY (%) | -34.0 | 61.2 | 62.7 | -28.3 | 62.0 |
Income Statement and Per-Share Data (Quarterly)
| Metric (INR Mn) | Q1FY2026 | Q2FY2026 | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|---|
Revenue from operations (INR Mn) | 5,263 | 5,590 | 6,120 | 5,786 | 6,828 |
Total income (INR Mn) | 5,376 | 5,653 | 6,167 | 5,846 | 6,920 |
EBITDA, aggregator (INR Mn) | 920 | 761 | 514 | 658 | 579 |
Profit before exceptional items & tax (INR Mn) | 751 | 0 | 0 | 592 | 510 |
PAT (INR Mn) | 558 | 542 | 326 | 449 | 379 |
EPS (INR) | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shareholders' equity (INR Mn) | 5,114 | 5,887 | 7,119 | 7,704 | 8,728 |
Book value per share (INR) | 204.56 | 235.48 | 284.77 | 308.14 | 349.12 |
Equity share capital (INR Mn) | 50 | 50 | 50 | 50 | 50 |
Balance-sheet Item Details
| Balance-sheet item | Status |
|---|---|
Total debt | No borrowings identified; "almost debt free" (Screener). Long-term D/E of 0.12 reported by an aggregator most likely reflects Ind AS 116 lease liabilities (office leases) |
Goodwill & intangibles | None material identified (no acquisitions) |
Cash Flow and Returns & Leverage Ratios (%)
| Metric (INR Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net change in cash, aggregator (INR Mn) | 960 | 520 | 50 | 310 | 0 |
Dividend declared for the year (INR Mn) | 250 | 400 | 600 | 800 | 900 |
Dividend payout ratio (%) | 40.6 | 40.3 | 37.2 | 69.1 | 48.0 |
Share buybacks (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on year-end equity (%) | 12.0 | 16.9 | 22.7 | 15.0 | 21.5 |
Debt / equity | ~0 (lease only) | ~0 | ~0 | ~0 | ~0.12 incl. leases (aggregator) |
Net debt / EBITDA | Net cash | Net cash | Net cash | Net cash | Net cash |
Interest coverage (Operating income ÷ interest expense, x) | 73 | 236 | 143 | 147 | 52 |
Revenue by Region and Region Margins & Growth (%)
| Geography (INR Mn) | FY2025 | FY2026 |
|---|---|---|
India — therapy-area product revenue (INR Mn) | 16,103 | 21,559 |
Residual: other operating revenue incl. overseas group services (INR Mn) | 1,060 | 1,197 |
Total revenue from operations (INR Mn) | 17,163 | 22,756 |
Geography growth (%) | FY2026 | — |
India therapy-area product revenue growth (%) | 33.9 | — |
Residual other operating revenue growth (%) | 12.9 | — |
Share Price History
| Date | Price (INR) | Source |
|---|---|---|
17 Nov 2025 | 9,135.00 | Bajaj Broking |
3 Apr 2026 | 7,827.50 | 5paisa |
10 Apr 2026 | 8,291.50 | Arihant |
22 Jul 2026 | 8,088.50 | Kotak Neo |
21 Aug 2026 | 7,415.50 | Bajaj Broking / Craytheon |
28 Aug 2026 | 7,121.10 | Anand Rathi |
23 Sep 2026 | 6,712.15 | Anand Rathi (last dated quote verified) |
Undated (likely Oct 2026) | 5,950.50 | Fyers (shows −34.8% over one year) — not date-verified |
Price performance | Value | Basis |
1-year return | −23.8% | Anand Rathi, as of 23 Sep 2026 |
6-month return | −19.0% | Anand Rathi, as of 23 Sep 2026 |
3-year price CAGR | ~8% | — |
5-year price CAGR | ~14% | Fyers |
10-year price CAGR | ~20% | Fyers |
52-week range | INR 6,606.30 – 9,850.00 | Anand Rathi, Sep 2026 |
All-time/earlier 52-week high | INR 10,691 | Screener / 5paisa |
Valuation Snapshot
| Multiple | Value | Computation |
|---|---|---|
Market capitalisation (INR Mn) | 167,804 | 6,712.15 × 25.0 M shares |
Trailing EPS (INR) | 67.85 | Q2 FY2026 21.69 + Q3 13.04 + Q4 17.95 + Q1 FY2027 15.17 |
P/E (TTM) | ~98.9x | Matches Anand Rathi 98.93 |
P/B | ~19.2x | On FY2026 BVPS INR 349.12 |
EV/Sales (TTM, cash not deducted) | ~6.9x | On TTM revenue INR 24,324 M |
EV/EBITDA (TTM, cash not deducted) | ~66.8x | On TTM aggregator EBITDA INR 2,512 M |
Dividend yield (FY2026 DPS) | ~0.54% | 36 ÷ 6,712 |
Dividend (INR per share)
| Dividend (INR per share) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 10 | 16 | 24 | 32 | 36 |
Capital Markets
| Item | Status |
|---|---|
Credit ratings (Moody's/S&P/Fitch; domestic CRISIL/ICRA/CARE) | None for the listed entity — no rated debt |
Debt maturity profile | Not applicable (no borrowings; lease liabilities only) |
Analyst consensus | Limited sell-side coverage; no verifiable consensus target or rating identified. Algorithmic "price target" websites are excluded as unreliable |
Free float | 25% (6.25 M shares); low liquidity (daily volumes of a few thousand to ~50,000 shares in Aug 2026) |
Analyst Conclusions
Management guidance
No quantitative guidance. Management messaging (Q1 FY2027 release and Oct 2026 press release) emphasises disciplined execution across Oncology, Biopharmaceuticals and Rare Disease, an innovation-led strategy, new access pathways and the Mumbai commercial hub.
Consensus expectations
No verifiable consensus. Based on run-rate, Q1 FY2027 revenue of INR 6,828 M annualises to ~INR 27,300 M (+20% on FY2026) even with zero sequential growth — this is a mechanical observation, not a forecast.
Bull case
-
Pipeline flow-through sustains 20%+ growth. FY2026 delivered 11 approvals; 2026 has already added Calquence (two indications) and Fasenra (two indications), and oncology grew 26% in Q1 FY2027 on a high base.
-
Margin troughing. Q1 FY2027 margin pressure was attributed to transitory factors (inventory drawdown, churn-related employee costs, FX). With manufacturing-exit costs behind it and SG&A historically growing far slower than revenue, operating leverage could restore EBITDA margins toward the 12–15% band seen in FY2023–FY2026.
-
Optionality from Rare Disease and new categories. Rare Disease jumped to INR 144 M in one quarter; Lokelma/Gimliand creates a two-channel hyperkalaemia franchise.
Bear case
-
Structural margin erosion. Gross margin has fallen ~21 points in three years as imported biologics dominate the mix; growth may continue to accrue mainly to the parent via transfer pricing.
-
Regulatory pricing hits. The Symbicort (INR 605 M alleged) and Betaloc-50 matters together could exceed a quarter's PAT if adverse.
-
Valuation without earnings growth. At ~99x trailing earnings with PAT down YoY in three of the last four quarters (Q3, Q4 FY2026; Q1 FY2027), further de-rating is plausible if margins don't recover.
Catalysts and monitorables (next 12 months)
-
Q2 FY2027 results (expected Nov 2026; date to be confirmed): EBITDA margin vs Q1's ~7.1%.
-
Appointment of a permanent CFO and replacement Medical Affairs director.
-
Outcome of the NPPA Symbicort show-cause; Delhi High Court hearing on Betaloc-50 (10 Feb 2027).
-
CDSCO approvals for further ADC/oncology assets.
-
Rare Disease quarterly run-rate and Lokelma uptake via Sun.
-
Disposition (sale) of the Bengaluru site and any one-off gain or loss.
-
FY2027 dividend recommendation (May 2027).
-
Any parent-level action on the 75% holding (no current indication).
Analyst verdict
AstraZeneca Pharma India is a high-quality growth franchise trapped inside a structurally thin-margin operating model. On the top line, few listed Indian pharma companies can match it: revenue has compounded at roughly 30% a year for four years, oncology is growing 26–44%, and the global parent is pushing an unusually dense stream of molecules and indications through CDSCO. The balance sheet is debt-free, the manufacturing exit is complete, and dividends have risen every year.
The problem is conversion. Because AZPIL imports finished product from its parent at transfer prices it does not control, incremental revenue — especially in high-cost ADCs and biologics — carries progressively less gross margin. That dynamic, plus FX, price-control enforcement and a costly wave of leadership turnover, produced three of the last four quarters with year-on-year PAT declines despite 20–39% revenue growth. Q1 FY2027's ~7% EBITDA margin is the lowest in the recent series.
The valuation does not leave room for that problem to persist. Even after a ~24% one-year decline, the stock trades near 99x trailing earnings and ~19x book, a premium justified only if margins return to the 12–15% range while growth stays above 20%. Minority shareholders also hold a structurally weak hand: the parent owns 75%, sets transfer prices and decides which assets sit in the listed entity.
Our synthesis: the fundamental trajectory is positive and the franchise is strategically important to AstraZeneca's Asia ambitions, but the next two quarters — specifically margin recovery, a stable CFO appointment, and resolution of NPPA matters — determine whether the premium is earned. Until margin evidence improves, the risk-reward is balanced at best, with the burden of proof on profitability rather than growth.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Prior roles / background | Notes |
|---|---|---|---|---|
Praveen Rao Akkinepally | Country President & Managing Director | From 1 Jul 2025 (three-year term) | 20+ years at AZ; joined as a microbiologist; Head of Oncology Business Unit, India; Head of Marketing for oncology brands (US); Global Head, Lung Cancer Commercialisation; FICCI Cancer Round Table contributor | — |
Bhavana Agrawal | Executive Director & CFO | Until close of business 31 Aug 2026 | Moving to a regional AZ Group role; resignation tendered 20 Jul 2026; holds no shares | Board approved a change in her designation on 10 Aug 2026 |
Tanya Sanish | Company Secretary & Compliance Officer | From 23 Feb 2026 | Replaced Manasa R. | — |
Praveen K. Mittal | Director, Corporate Affairs | From 6 Jul 2026 | 30 years in healthcare/medtech policy; 18+ years at FICCI as Assistant Secretary General | Replaced Ajay Sharma (resigned 26 Nov 2025) |
Shikha Mirchandani Chatrath | Director – Commercial Excellence, BD & Strategy | Appointed FY2025 | — | Per FY2025 release |
Amita Bhave | Head, Regulatory Affairs | Appointed FY2025 | — | — |
Harish Dash | Senior Director, Commercial IT & Digital | From 3 Mar 2025 | — | — |
Amarpreet Kaur Ahuja | Country HR Director | — | Recognised in industry HR listing (FY2025) | — |
Executive Leadership Team
| Name | Role | Exit date | Context |
|---|---|---|---|
Dr Sanjeev Kumar Panchal | MD & Country President | 30 Jun 2025 | Moved to global AZ role (US) |
Pankaj Jain | Head – Legal | 31 Oct 2025 | Resigned |
Ajay Sharma | Director – Corporate Affairs | 26 Nov 2025 | Resigned |
Aditi Mehta | Senior leader (reported variously as Oncology Director / HR) | 12 Jun 2026 | Resigned; role description inconsistent across secondary sources |
Srikanth B.S. | Senior leader (reported as site/operations or supply-chain lead) | 15 Jun 2026 | Resigned |
Bhavana Agrawal | ED & CFO | 31 Aug 2026 | Regional AZ role |
Dr Sandeep Arora | Director – Medical Affairs, Biopharma & Rare Disease BUs | 15 Sep 2026 | Resigned to pursue external opportunity; replacement search under way |
Board of Directors — Shilpa Divekar Nirula
| Name | Category | Notes |
|---|---|---|
Shilpa Divekar Nirula | Chairperson, Independent Director | ID since 29 Dec 2021; Chair since 30 Sep 2024; re-appointed for second five-year term from 29 Dec 2026 (AGM Aug 2026) |
Revathy Ashok | Independent Director | Co-opted Dec 2016; second-term completion timing should be monitored under the 10-year ID cap |
Monica Widhani | Independent Director | Appointed FY2025 |
Praveen Rao Akkinepally | Managing Director | From 1 Jul 2025; DIN 11137771 |
Bhavana Agrawal | Executive Director (designation changed Aug 2026; CFO role ended 31 Aug 2026) | — |
Arun Krishna | Non-Executive (Additional) Director; AZ Area Vice President, Asia | Appointed Aug 2026 |
Hooi Bien Chuah | Non-Executive, non-independent Director (AZ nominee) | Reappointed by rotation, AGM 2025 |
Jesus Javier Diaz Ropero Esteso | Non-Executive Director (AZ nominee) | Appointed FY2025 |
Major Shareholders
| Holder category | % of equity |
|---|---|
AstraZeneca Pharmaceuticals AB, Sweden (foreign promoter) | 75.00 |
Institutions (total) | 8.76 |
— of which mutual funds (latest pattern quoted) | ~6.01 |
— of which foreign portfolio investors (May 2026) | ~2.70 |
Non-institutions (retail, HNI, corporates) | 16.23 |
Number of shareholders | ~29,338 |
Ownership trend (%) | Jun2025 |
Promoter holding (%) | 75.00 |
Institutional holding (%) | 7.58 |
Non-institutional holding (%) | 17.41 |
Competitive Landscape
Competitors by Segment
| Segment | Direct competitors in India | Nature of competition |
|---|---|---|
Oncology — lung (EGFR, IO) | Roche (unlisted India affiliate), MSD (Keytruda), Bristol-Myers Squibb, Novartis, Pfizer Ltd; domestic generics/biosimilars (Dr. Reddy's, Natco, Zydus, Intas, Biocon, Hetero) | Innovator class competition + Indian generics of off-patent agents |
Oncology — breast/HER2 & ADCs | Roche (trastuzumab/T-DM1), Novartis (CDK4/6), Pfizer, Eli Lilly; biosimilar trastuzumab makers (Biocon, Intas, Zydus) | Enhertu competes against biosimilar-anchored HER2 market |
Oncology — haematology (BTK) | Johnson & Johnson (ibrutinib), BeiGene (zanubrutinib), AbbVie; Indian ibrutinib generics | Calquence positioned on tolerability |
CVRM — SGLT2/diabetes | Boehringer Ingelheim/Lupin (empagliflozin), Sun Pharma, Mankind, Glenmark, Torrent, Alkem, Cipla, Dr. Reddy's (generic dapagliflozin/empagliflozin) | Intense generic price competition |
CVRM — antiplatelet/beta-blockers | Sun Pharma, Torrent, Cipla, Lupin, Intas | Price-controlled, branded generics |
CVRM — hyperkalaemia | — | Early-market category creation |
R&I — inhalers | Cipla (market leader in inhalation), Glenmark, Lupin, GSK Pharmaceuticals | Cipla dominance; Mankind channel for Symbicort |
R&I — biologics (severe asthma) | GSK (mepolizumab), Sanofi (dupilumab), Novartis (omalizumab) | Specialist biologic competition |
Rare disease (complement) | Biosimilar eculizumab entrants (e.g., Intas), Novartis (iptacopan) | Price and access |
Competitor Detail
| Benchmark | AZPIL (FY2026) |
|---|---|
Revenue (INR Mn) | 22,756 |
Revenue growth (%) | 32.6 |
Net margin (%) | 8.2 |
R&D intensity | Negligible at listed level |



